FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer - Sorbonne Université
Journal Articles Digestive and Liver Disease Year : 2022

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer

1 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
2 Institut Bergonié [Bordeaux]
3 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
4 FFCD - Fédération Francophone de Cancérologie Digestive
5 Service d'Oncologie médicale [CHU Henri Mondor]
6 IMRB - Institut Mondor de Recherche Biomédicale
7 Inserm U955 - Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18)
8 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
9 CHU Amiens-Picardie
10 UNIGE - Université de Genève = University of Geneva
11 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
12 IPC - Institut Paoli-Calmettes
13 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
14 IDESP - Institut Desbrest de santé publique
15 AP-HP - Hopital Saint-Louis [AP-HP]
16 Hôpital Haut-Lévêque [CHU Bordeaux]
17 HCL - Hospices Civils de Lyon
18 LaTIM - Laboratoire de Traitement de l'Information Medicale
19 OSS - Oncogenesis, Stress, Signaling
20 CRLCC - CRLCC Eugène Marquis
21 Centre Hospitalier Universitaire [Rennes]
22 Hôpital Ambroise Paré [AP-HP]
23 BECCOH - Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
24 HEGP - Hôpital Européen Georges Pompidou [APHP]
25 CHU Trousseau [Tours]
26 CRSA - Centre de Recherche Saint-Antoine
27 FHU PaCeMM - Paris Center for Microbiome Medicine
28 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
Simon Pernot
Vincent Hautefeuille
Thomas Aparicio
Denis Smith
  • Function : Author
  • PersonId : 1025574
Claude Capron
  • Function : Author
  • PersonId : 936711
Theodora Bejan-Angoulvant
Julien Taieb
  • Function : Author
  • PersonId : 1138108

Abstract

Immune checkpoint inhibitors (ICI) have high efficacy in metastatic colorectal cancer (mCRC) with microsatellite instability (MSI) but not in microsatellite stable (MSS) tumour due to the low tumour mutational burden. Selective internal radiation therapy (SIRT) could enhance neoantigen production thus triggering systemic anti-tumoral immune response (abscopal effect). In addition, Oxalipatin can induce immunogenic cell death and Bevacizumab can decrease the exhaustion of tumour infiltrating lymphocyte. In combination, these treatments could act synergistically to sensitize MSS mCRCs to ICI SIRTCI is a prospective, multicentre, open-label, phase II, non-comparative single-arm study evaluating the efficacy and safety of SIRT plus Xelox, Bevacizumab and Atezolizumab (anti-programmed death-ligand 1) in patients with liver-dominant MSS mCRC. The primary objective is progression-free survival at 9 months. The main inclusion criteria are patients with MSS mCRC with liver-dominant disease, initially unresectable disease and with no prior oncologic treatment for metastatic disease. The trial started in November 2020 and has included 10 out of the 52 planned patients.
Fichier principal
Vignette du fichier
Randrian et al - 2022 - FFCD 1709-SIRTCI phase II trial.pdf (235.99 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03906999 , version 1 (24-01-2023)

Identifiers

Cite

Violaine Randrian, Simon Pernot, Karine Le Malicot, Vittorio Catena, Isabelle Baumgaertner, et al.. FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54 (7), pp.857-863. ⟨10.1016/j.dld.2022.04.024⟩. ⟨hal-03906999⟩
206 View
219 Download

Altmetric

Share

More